Citation Impact
Citing Papers
Place of Cabergoline in Acromegaly: A Meta-Analysis
2011
Partial Surgical Removal of Growth Hormone-Secreting Pituitary Tumors Enhances the Response to Somatostatin Analogs in Acromegaly
2006
Guidelines for Acromegaly Management: An Update
2009
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
2009
Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
2010
A consensus on the diagnosis and treatment of acromegaly complications
2012
Acromegaly
2006 Standout
Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications
2013
Morbidity after Long-Term Remission for Acromegaly: Persisting Joint-Related Complaints Cause Reduced Quality of Life
2005
Pegvisomant and cabergoline combination therapy in acromegaly
2012
The Antitumoral Effects of Somatostatin Analog Therapy in Acromegaly
2005
Radiotherapy and radiosurgery in acromegaly
2008
Consensus statement: medical management of acromegaly
2005
Acromegaly and Pregnancy: A Retrospective Multicenter Study of 59 Pregnancies in 46 Women
2010
Pharmacotherapy or Surgery as Primary Treatment for Acromegaly?
2000
Radiotherapy for Pituitary Adenomas
2008
Cushing's syndrome
2015 Standout
Molecular defects in the pathogenesis of pituitary tumours
2003
Cabergoline Decreases Somatotroph Adenoma Size: A Case Report
2004
Variation in GH and IGF‐I assays limits the applicability of international consensus criteria to local practice
2007
Predictors of Tumor Shrinkage after Primary Therapy with Somatostatin Analogs in Acromegaly: A Prospective Study in 99 Patients
2006
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegaly
2007
Comparison between Six-Year Therapy with Long-Acting Somatostatin Analogs and Successful Surgery in Acromegaly: Effects on Cardiovascular Risk Factors
2006
Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR®
2008
Gamma knife radiosurgery for acromegaly – long‐term experience
2006
Long-Term Evaluation of Postoperative Acromegalic Patients in Remission with Previous and Newly Proposed Criteria
2005
Primary medical therapy for acromegaly
2003
Raloxifene decreases serum IGF-I in male patients with active acromegaly
2004
Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
2013 Standout
Insulin and insulin-like growth factor signalling in neoplasia
2008 Standout
Primary Treatment of Acromegaly with Octreotide LAR: A Long-Term (Up to Nine Years) Prospective Study of Its Efficacy in the Control of Disease Activity and Tumor Shrinkage
2006
Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature
2011
Cabergoline Therapy of Growth Hormone & Growth Hormone/Prolactin Secreting Pituitary Tumors
2004
Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
2011 Standout
Nelson’s Syndrome: Complete Remission with Cabergoline but Not with Bromocriptine or Cyproheptadine Treatment
2004
Acromegaly: An Endocrine Society Clinical Practice Guideline
2014 Standout
Induction of laminitis by prolonged hyperinsulinaemia in clinically normal ponies
2007 Standout
Long-Acting Somatostatin Analog Therapy of Acromegaly: A Meta-Analysis
2005
Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status
2004
Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
2012
Pituitary pars intermedia dysfunction: equine Cushing's disease
2002
Efficacy and tolerability of gamma knife radiosurgery in acromegaly: a 10‐year follow‐up study
2009
Stereotactic Radiosurgery for Pituitary Adenomas: A Review of the Literature
2004
Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors
2004
Effects of two different somatostatin analogs on glucose tolerance in acromegaly
2002
Effects of octreotide exposure during pregnancy in acromegaly
2009
Pregnancy and acromegaly: a review
2011
The long‐term efficacy of conventional radiotherapy in patients with GH‐secreting pituitary adenomas
2005
Cushing's syndrome
2006 Standout
Growth hormone and the heart
2001
Gamma knife stereotactic radiosurgery for acromegaly
2007
Radiosurgery of growth hormone–producing pituitary adenomas: factors associated with biochemical remission
2007
A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly
2008
Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly
2002
Optimizing Control of Acromegaly: Integrating a Growth Hormone Receptor Antagonist into the Treatment Algorithm
2003
Forty Month Follow-Up of Persistent and Difficultly Controlled Acromegalic Patients Treated with Depot Long Acting Somatostatin Analog Octreotide
2007
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
2004 Standout
A Consensus on Criteria for Cure of Acromegaly
2010
Gamma-Knife Radiosurgery in Acromegaly: A 4-Year Follow-Up Study
2003
Growth of an aggressive tumor during pregnancy in an acromegalic patient
2012
Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study
2010
Lanreotide 60 mg, a New Long-Acting Formulation: Effectiveness in the Chronic Treatment of Acromegaly
2003
Acromegaly: historical perspectives and current therapy
2001
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
2014
Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates
2006
A Critical Analysis of Pituitary Tumor Shrinkage during Primary Medical Therapy in Acromegaly
2005
Guidelines for Perioperative Care in Elective Rectal/Pelvic Surgery: Enhanced Recovery After Surgery (ERAS®) Society Recommendations
2012 Standout
Treatment of Acromegaly with Pegvisomant during Pregnancy: Maternal and Fetal Effects
2007
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 Update
2011
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
2012
The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism
2016 Standout
Works of M Barausse being referenced
Pregnancy in acromegaly: a one-center experience
2006
GH/IGF-I normalization and tumor shrinkage during longterm treatment of acromegaly by lanreotide
2001
Lanreotide 60 mg, a Longer-Acting Somatostatin Analog: Tumor Shrinkage and Hormonal Normalization in Acromegaly
2000
Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?
1998
From macroprolactinoma to concomitant ACTH-PRL hypersecretion with Cushing’s disease
2000
Failure of radiotherapy in acromegaly
2001
Neurosurgery restores late GH rise after glucose-induced suppression in cured acromegalics
1999
Four-Year Treatment with Octreotide-Long-Acting Repeatable in 110 Acromegalic Patients: Predictive Value of Short-Term Results?
2003
Raloxifene lowers IGF-I levels in acromegalic women
2003
Estroprogestinic pill normalizes IGF-I levels in acromegalic women
2003
A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly
1999